Literature DB >> 7890899

Vasopressin release and water metabolism in patients with cirrhosis.

F Salerno1, A Del Bo, A Maggi, M Marabini, M Maffi, G M Borroni, P Moser.   

Abstract

Water retention is a complication in many patients with cirrhosis, usually attributed to excessive release of arginine vasopressin. To investigate the responsiveness of arginine vasopressin to osmotic and non-osmotic stimuli and its relationship to free water excretion, we studied 19 patients with cirrhosis under three different conditions: 45 min with legs raised to 60 degrees, to expand the central blood volume; infusion of 1000 ml of 0.45% saline solution to reduce plasma osmolality; and rapid injection of 50 ml of 2 M NaCl to increase plasma osmolality. Both expansion of central blood volume and decrease of plasma osmolality significantly reduced plasma vasopressin levels (from 2.1 +/- 0.6 to 1.39 +/- 0.3 pg/ml, p < 0.04; and from 1.09 +/- 0.25 to 0.41 +/- 0.13 pg/ml, p < 0.0001). The changes in free water excretion differentiated two subgroups of patients during each test: excretors and non-excretors. In the excretors, increased free water excretion was associated with suppressed vasopressin levels (below 0.5 pg/ml) and normal renal function. In the non-excretors, inability to improve free water excretion was associated with high vasopressin levels or with reduced distal delivery of the glomerular filtrate, except in some cases where vasopressin levels had fallen below 0.5 pg/ml and renal function was normal. For these cases the presence of other vasopressin-independent antidiuretic mechanisms is conceivable. The injection of hypertonic saline solution caused significant rises in plasma osmolality (from 287 +/- 1.9 to 292 +/- 1.6 mmol/kg, p < 0.05) and in plasma vasopressin levels (from 1.13 +/- 0.29 to 2.86 +/- 0.52 pg/ml, p < 0.05). These results suggest that vasopressin release in patients with cirrhosis is normally responsive to osmotic and non-osmotic stimuli, although our results show a lower theoretical osmolar threshold for suppression of vasopressin release in non-excretors than in excretors (276 vs 284 mmol/kg).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7890899     DOI: 10.1016/s0168-8278(94)80245-9

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  3 in total

Review 1.  Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Authors:  Elaine Yeung; Elaine Yong; Florence Wong
Journal:  MedGenMed       Date:  2004-12-02

2.  Predictive value of the efficacy of tolvaptan in liver cirrhosis patients using free water clearance.

Authors:  Hisamitsu Miyaaki; Yutaka Nakamura; Tatsuki Ichikawa; Naota Taura; Satoshi Miuma; Hidetaka Shibata; Takuya Honda; Kazuhiko Nakao
Journal:  Biomed Rep       Date:  2015-09-28

3.  Long-term administration of Tolvaptan to patients with decompensated cirrhosis.

Authors:  Kengo Kanayama; Tetsuhiro Chiba; Kazufumi Kobayashi; Keisuke Koroki; Susumu Maruta; Hiroaki Kanzaki; Yuko Kusakabe; Tomoko Saito; Soichiro Kiyono; Masato Nakamura; Sadahisa Ogasawara; Eiichiro Suzuki; Yoshihiko Ooka; Shingo Nakamoto; Shin Yasui; Tatsuo Kanda; Hitoshi Maruyama; Jun Kato; Naoya Kato
Journal:  Int J Med Sci       Date:  2020-03-15       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.